title: Clinical outcome of chemoradiation therapy in patients with limited-disease small cell lung cancer with ipsilateral pleural effusion.
abstract: BACKGROUND
  The indications for definitive thoracic radiotherapy (TRT) in limited-disease small cell lung cancer (LD-SCLC) and ipsilateral pleural effusion have not been thoroughly investigated. We retrospectively investigated the clinical outcome of LD-SCLC patients with ipsilateral pleural effusion.
  
  
  METHODS
  The medical records of SCLC patients who received treatment at the National Cancer Center Hospital East between July 1992 and December 2006 were reviewed. Sixty-three of the 373 LD-SCLC patients (17%) had ipsilateral pleural effusion. Of these, 62 patients received chemotherapy as an initial treatment, and were included in this study. Since about 1998, definitive TRT was routinely performed if the patient's pleural effusion disappeared after induction chemotherapy. The 62 patients were divided into three subgroups: group A included patients who received chemotherapy and TRT (n = 26), group B included patients who did not receive TRT in spite of the disappearance of pleural effusion after first-line chemotherapy (n = 8), and group C included patients who did not receive TRT and whose pleural effusion persisted after first-line chemotherapy (n = 28).
  
  
  RESULTS
  The response rate for first-line chemotherapy was 74%. Ipsilateral pleural effusion disappeared after first-line chemotherapy in 34 patients (55%). The median overall survival time was 11.8 months, and the 2 and 3-year survival rates were 21 and 10%, respectively. In groups A, B, and C, the median survival times were 19.2, 10.5, and 9.2 months, respectively, and the 2-year survival rates were 38, 25, and 7%, respectively.
  
  
  CONCLUSIONS
  Long-term survival was achieved by LD-SCLC patients with ipsilateral pleural effusion who successfully underwent chemoradiotherapy.
authors.affiliation: Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. siniho@east.ncc.go.jp
authors.forename: Seiji
authors.initials: S
authors.lastname: Niho
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kubota
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Yoh
authors.forename: Koichi
authors.initials: K
authors.lastname: Goto
authors.forename: Hironobu
authors.initials: H
authors.lastname: Ohmatsu
authors.forename: Keiji
authors.initials: K
authors.lastname: Nihei
authors.forename: Nagahiro
authors.initials: N
authors.lastname: Saijo
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nishiwaki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000150:complications / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000150:complications* / Q000175:diagnosis; D015996:Survival Rate